Trevi Therapeutics, Inc.
TRVIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary. Valued at $1.80B, TRVI is a small-cap name in its sector. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Market Cap
$1.80B
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-21.85
EPS (TTM)
$-0.35
EPS (Fwd)
$-0.58
ROE
-19.7%
ROA
-13.8%
Cash
$318.9M
Total Debt
$605,000
Free CF
-$33.3M
52W Change
20.0%
Annual Financials
Cash vs Debt
Where TRVI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TRVI finished 22.12% below its 150-day moving average ($15.28) and 16.61% below its 200-day moving average ($14.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TRVI overbought or oversold?
At the October 20, 2026 close, TRVI's RSI(14) was 12.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Trevi Therapeutics, Inc. holds $318.9M in cash against $605K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$33.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -19.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Trevi Therapeutics, Inc. and its sector.